Contineum Therapeutics CEO exercises options, sells shares
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Contineum Therapeutics, Inc. CEO and President Carmine N. Stengone exercised stock options for 2,500 shares of Class A common stock at an exercise price of $1.01 per share and sold 2,500 shares at a weighted average price of $16.0116 per share, with trades between $16.00 and $16.06. The options were granted under the company’s 2012 Equity Incentive Plan and are fully vested, leaving 276,930 options outstanding after the exercise. All reported transactions on August 3, 2026 were executed under a Rule 10b5-1 trading plan adopted on September 23, 2025.
Insider Trade Summary 10b5-1
Exercise and Sale: 2,500 shares ($38K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Stengone Carmine N.
Role
CEO and President
Sold
2,500 shs ($40K)
Approx. gross sale proceeds
$40K
Approx. exercise cost
$3K
Approx. pre-tax spread
$38K
Share of Position Sold
12.7%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1, F3 | 2,500 | $0.00 | $0.00 |
| Exercise | Class A Common Stock F1 | 2,500 | $1.01 | $3K |
| Sale | Class A Common Stock F1, F2 | 2,500 | $16.0116 | $40K |
Holdings After Transaction:
Stock Option (right to buy) — 276,930 contracts (Direct);
Class A Common Stock — 17,217 shares (Direct)
Holdings Before and After:
Stock Option (right to buy), 279,430 to 276,930 contracts (Direct);
Class A Common Stock, 17,217 to 17,217 shares (Direct)
Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (3)
- F1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.06, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F3. Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.
Key Figures
Options exercised: 2,500 shares
Option exercise price: $1.01 per share
Shares sold: 2,500 shares
+4 more
7 metrics
Options exercised
2,500 shares
Stock options exercised into Class A common stock on 2026-08-03
Option exercise price
$1.01 per share
Exercise price for 2,500 stock options converted on 2026-08-03
Shares sold
2,500 shares
Class A common stock sold on 2026-08-03 following option exercise
Weighted average sale price
$16.0116 per share
Weighted average for sales in the $16.00–$16.06 range
Remaining options
276,930 options
Stock options remaining after the 2,500-share exercise
Option expiration date
2030-02-24
Expiration date of the stock option award exercised in part
10b5-1 plan adoption date
September 23, 2025
Date CEO adopted the Rule 10b5-1 trading plan governing these trades
Key Terms
Rule 10b5-1 trading plan, weighted average price, Equity Incentive Plan, Stock Option (right to buy)
4 terms
Rule 10b5-1 trading plan financial
"These transactions were effected pursuant to a 10b5-1 trading plan adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Equity Incentive Plan financial
"Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan")."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Contineum Therapeutics (CTNM) report for its CEO on this Form 4?
Carmine N. Stengone, Contineum Therapeutics’ CEO, exercised options for 2,500 shares and sold 2,500 Class A shares on August 3, 2026. The sale followed the option exercise and was carried out under a pre-established Rule 10b5-1 trading plan.
At what price did the Contineum Therapeutics (CTNM) CEO exercise stock options on this Form 4?
The Form 4 shows the CEO exercised 2,500 stock options at an exercise price of $1.01 per share. These options were granted under Contineum Therapeutics’ 2012 Equity Incentive Plan and were fully vested at the time of exercise.
How many stock options does the Contineum Therapeutics (CTNM) CEO still hold after this transaction?
After exercising 2,500 options, the CEO holds 276,930 stock options related to this award. These options were granted under the 2012 Equity Incentive Plan and are reported with an expiration date of February 24, 2030 in the Form 4.
Were the Contineum Therapeutics (CTNM) CEO’s trades made under a Rule 10b5-1 trading plan?
Yes. The Form 4 states that all reported transactions were effected pursuant to a Rule 10b5-1 trading plan. The plan was adopted by the CEO on September 23, 2025, providing a pre-arranged framework for the August 3, 2026 trades.
What is the expiration date of the Contineum Therapeutics (CTNM) stock options exercised by the CEO?
The stock options exercised for 2,500 shares carry an expiration date of February 24, 2030. They were granted under Contineum Therapeutics’ 2012 Equity Incentive Plan and, according to the Form 4 footnote, were already fully vested when exercised.
AI-generated analysis. How Rhea-AI works. Not financial advice.
